Medical Stock Update On AVII, ALXN and PROT From

PennyToBuck Medical Stock Update On PROT, ALXN, AVII.
Spread the Word
Listed Under

Alexion Pharmaceuicals
Avi Biopharma
Department Of Defense


Aug. 23, 2010 - PRLog -- Proteonomix, Inc.  entered into an agreement with a group of investors that will create a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). The Investor Group has committed to invest $5 million on or before September 10,2010. The Joint Venture company, XGen Medical LLC (”XGen“), a Nevis Island limited liability company, will be owned 51% by Proteonomix and 49% by the Investor Group.

The Investor Group’s $5 million cash investment includes the purchase of $1 million of cellular material from Proteonomix.

Additionally, as part of the agreement PROT will license to XGen, both a use and treatment license in the U.A.E., as well as a license to manufacture the cellular material.

The agreement calls for PROT, through its wholly owned subsidiary, StromaCel, Inc. to receive $ 7,500 per treated patient.

There is also provision made for the distribution of Proteoderm, PROT’s new Anti-aging line of skin care products. including Proteoderm’s Matrix NC-138 (click here) anti-aging products.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site,, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit,, and

Alexion Pharmaceuticals, Inc.  announced that the US Food and Drug Administration (FDA) has approved ALXN’s Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris (eculizumab). Earlier this year, ALXN reported that the European Medicines Agency had approved ARIMF as a second source of supply for Soliris in the European Union (EU). In addition to sourcing Soliris from ARIMF, ALXN will maintain its agreement with its long-time contract manufacturer; either source can now meet all of ALXN’s forecasted commercial and clinical needs for Soliris in the US and EU, which territories accounted for more than 90% of ALXN’s 2009 revenues. Additionally, ALXN has applied for regulatory approvals for ARIMF in other countries where it has, or is establishing, commercial operations.

Soliris is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, debilitating and life-threatening blood disorder. Soliris was approved by the FDA and the European Commission in 2007, as well as by the regulatory authorities of other countries, including Japan's Ministry of Health, Labour and Welfare (MHLW) in 2010. In addition, more than a dozen clinical studies of Soliris as a treatment for patients with other severe and ultra-rare disorders are currently underway in areas that include nephrology and transplant. Among these are clinical studies with Soliris treatment of two cohorts of patients with atypical hemolytic uremic syndrome (aHUS) as well as transplant patients at elevated risk of antibody-mediated graft rejection.

Soliris (eculizumab) is a first-in-class terminal complement inhibitor developed from the laboratory through regulatory approval by Alexion. Soliris has been approved by the healthcare authorities in the U.S., European Union, Japan and other countries as the first treatment for patients with PNH, an ultra-rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. Prior to these approvals, there was no therapy specifically available for the treatment of PNH. More information on Soliris is available at

This press release and further information about Alexion Pharmaceuticals, Inc. can be found at:

AVI BioPharma, Inc. , a developer of RNA-based therapeutics, today announced the publication online in Nature Medicine of new preclinical data demonstrating that AVI-6002 and AVI-6003, the respective lead therapeutic candidates against Ebola and Marburg viruses, both employing AVII's advanced PMOplus chemistry, provide post exposure efficacy in non-human primates. Treatment of Ebola virus-infected primates with AVI-6002 led to 60% survival, and treatment of Marburg-infected primates with AVI-6003 conferred 100% survival, compared to control groups where both viruses were universally lethal. In addition to survival, AVI-6002 and AVI-6003 demonstrated improvements in levels of viremia, harmful inflammatory indicators and measurements of virus induced liver damage.

The work was a collaborative effort between AVII and scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the Department of Defense's (DoD) lead medical research laboratory for biological defense. All preclinical studies were conducted at USAMRIID, which has the DoD's only Biosafety Level 4, or maximum containment, capability -- essential for studying the Ebola and Marburg viruses.

J. David Boyle II, Interim President and Chief Executive Officer of AVI BioPharma commented "These studies provide further evidence of the potential of our advanced PMOplus™ chemistry, coupled with our RNA-based technologies, as a unique and important platform for the research and development of novel anti-infective therapeutics."

For more information, visit

For more information, visit

For FREE Daily Stock Alerts & Updates Signup At:


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.  Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

Like PRLog?
Click to Share